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Abstract
Background: Ionizing radiation (IR) in combination with microtubule stabilizing agents (MSA) is a promising
combined treatment modality. Supra-additive treatment responses might result from direct tumor cell killing and
cooperative indirect, tumor cell-mediated effects on the tumor microenvironment. Here we investigated
deregulation of matrix metalloproteinase (MMP) activity, as an important component of the tumor
microenvironment, by the combined treatment modality of IR with the clinically relevant MSA patupilone.
Methods: Expression, secretion and activity of MMPs and related tissue inhibitors of metalloproteinases (TIMPs)
were determined in cell extracts and conditioned media derived from human fibrosarcoma HT1080 and human
glioblastoma U251 tumor cells in response to treatment with IR and the MSA patupilone. Treatment-dependent
changes of the invasive capacities of these tumor cell lines were analysed using a Transwell invasion assay. Control
experiments were performed using TIMP-directed siRNA and TIMP-directed inhibitory antibodies.
Results: Enzymatic activity of secreted MMPs was determined after treatment with patupilone and irradiation in the
human fibrosarcoma HT1080 and the human glioblastoma U251 tumor cell line. IR enhanced the activity of
secreted MMPs up to 2-fold and cellular pretreatment with low dose patupilone (0.05-0.2 nM) counteracted
specifically the IR-induced MMP activity. The cell invasive capacity of HT1080 and U251 cells was increased after
irradiation with 2 Gy by 30% and 50%, respectively, and patupilone treatment completely abrogated IR-induced cell
invasion. Patupilone did not alter the level of MMP expression, but interestingly, the protein level of secreted
TIMP-1 and TIMP-2 was lower after combined treatment than after irradiation treatment alone. Furthermore, siRNA
depletion of TIMP-1 or TIMP-2 prevented IR-mediated induction of MMP activity and cell invasion.
Conclusions: These results indicate that patupilone counteracts an IR-induced MMP activation process by the
reduction of secreted TIMP-1 and TIMP-2 proteins, which are required for activation of MMPs. Since IR-induced
MMP activity could contribute to tumor progression, treatment combination of IR with patupilone might be of
great clinical benefit for tumor therapy.
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Background
Interference with microtubular (MT) function represents
a clinically relevant anticancer strategy, as demonstrated
by the use of taxanes for the treatment of a wide variety
of human malignancies [1-3]. Epothilones are nontaxoid
MSAs of bacterial origin, which share the same binding
site on β-tubulin with taxanes [4,5] and also promote
tubulin polymerization and stabilization of already formed
MTs [6]. Members of the epothilone family, including
patupilone (epothilone B), have been tested in multiple
clinical trials [7-13], Combined application of patupilone
with ionizing radiation (IR) is a promising combined
treatment modality for cancer therapy, as previously
investigated in our laboratory in different tumor
models such as lung and colon adenocarcinoma and
medulloblastoma. The combined treatment modality
results in strong supra-additive growth inhibition of
murine tumor xenografts [14-16]. Interestingly though,
combined cytotoxicity is much less pronounced on the
cellular level in vitro, indicating that an additional effect
occurs on the level of the tumor microenvironment.
Further investigations revealed that patupilone treatment
inhibits VEGF-secretion from the tumor cells thereby
contributing to the supra-additive cytotoxicity of the
combined treatment modality observed in vivo [14].
Microtubule interference with MSA could deregulate
the secretion of biologically active factors [14,17,18]. We
recently demonstrated that patupilone counteracts
stress-induced VEGF expression and secretion from
patupilone-sensitive tumor cells [19]. Furthermore, MSA
could disturb the secretion of matrix metalloproteinase
thereby affecting the tumor microenvironment (see
below) [20-22].
Matrix metalloproteinases (MMPs) are zinc-dependent
endopeptidases with a broad variety of substrates including
components of the extracellular matrix and growth
factors, such as the transforming growth factor β
(TGF- β). MMPs play an important role in cell survival,
apoptosis, angiogenesis, matrix remodelling and metastasis
and are regulated at several levels including transcriptional
and posttranslational mechanisms and by endogenous
tissue inhibitors of metalloproteinases (TIMPs) [23-25].
TIMPs, a family of proteins containing 4 members,
TIMP1-4, inhibit MMP-activity by binding to the catalytic
domain of active MMPs. However, TIMP-2 is also known
to be a co-activator of MMP-2 zymogen in an MT1-MMP
(MMP-14)-dependent proMMP-2 activation process [26].
Additionally, TIMPs have MMP independent biological
functions, including mitogenic [27] and pro- and anti-
apoptotic functions [28,29]. MMPs and TIMPs are secreted
by tumor-associated stromal and cancer cells and are
important components of the tumor microenvironment.
Secretion of MMPs and TIMPs is partially executed
in vesicles along the MT-cytoskeleton and is therefore
a potential target for MSAs. Overexpression of MMPs
and TIMPs is associated with a poor survival prognosis
for almost all tumor types [23]. In preclinical and
clinical studies, IR was demonstrated to upregulate
MMPs [30,31], and enhanced levels of MMPs were
detected in patients with lung and breast cancer after
radiotherapy [32]. Thus, IR might contribute to a potential
prometastatic effect.
Here we investigated the effect of patupilone and IR on
MMP function in vitro. We demonstrated that patupilone
inhibits both IR-induced MMP activity and IR-induced
cell invasion of human fibrosarcoma and glioma cell
lines. Furthermore, we analysed the mechanisms of the
inhibitory effect of patupilone and demonstrated that
patupilone counteracts IR-upregulated MMP-activity by
interfering with TIMP-1 and TIMP-2 secretion.
Methods
Cell culture
The human fibrosarcoma cells HT1080 (ATCC No
CCL-121) were grown in IMDM media. Human glioma
cells U251 was cultured in DMEM media. Media was
supplemented with 10% (v/v) FCS and 1% (v/v)
penicillin-streptomycin. All cell culture media and sup-
plements were obtained from Gibco (Invitrogen). Cells
were grown at 37°C in a 5% CO2 humidified atmosphere.
For control of identity, all cells throughout the course of
the studies were monitored for cell morphology and
growth pattern. Cells were cultured for not more than
10 passages.
To prepare conditioned cell culture media (CM) cells
were pretreated with or without patupilone for 24 h and
sham-treated or irradiated with the indicated doses of IR.
The cell culture media was discarded 1 h after irradiation
and cells were incubated for an additional 24 h in
serum-free Ultraculture medium (Lonza, Fischer Scientific).
Conditioned cell culture medium was collected, centrifuged
at 10’000 g for 5 min at 4°C and supernatants were stored
at −80°C.
Transfection
Transfection was performed using Lipofectamine 2000
(Invitrogen). siRNAs for downregulation of human
TIMP-1 (GenBank BC000866.1) and human TIMP-2
(GenBank BC052605.1) were synthesized by Microsynth
(Switzerland). siRNA against firefly luciferase (siLuc) was
used for control transfection. siRNA sequences (5′-3′):
siTIMP-1#1 GAUGUAUAAAGGGUUCCAAdTdT [33]
siTIMP-2#1 GGCACAUUAUGUAAACAUAdTdT [33]
siLuc CGTACGCGGAATACTTCGAdTdT
(Microsynth).
siRNAs were designed using Microsynth siRNA
Design Tool.
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Treatment modality
Irradiation was performed at room temperature using an
Xstrahl 200 kV X-ray unit (Gulmay Medical) at 1 Gy/
min. Patupilone was provided by Novartis Pharma AG
(Basel, Switzerland).
Clonogenic survival assay
Clonogenic survival assay was performed as described
previously [14]. 24 h after plating, cells were treated with
increasing concentrations of patupilone and irradiated
24 h later. Colonies were allowed to grow under normal
cell culture conditions for 7–10 days before fixation with
methanol/acetic acid (75%/25% v/v) and staining with 2%
crystal violet. Colonies with more than 50 cells were
counted manually. For the determination of the synergistic
effect, the earlier described model of synergy was used [34].
MMP activity assay
MMP activity in the CM was determined using a FRET-
based MMP activity assay (SensoLyte MMP-2 assay kit,
AnaSpec). According to the kit-description the peptide
substrate can be cleaved by multiple MMPs and was
used for the determination of pooled MMP activity. The
substrate cleavage reaction was performed according to
the manufacture’s instructions. The fluorescent signal
was measured in a Tecan GENios spectrophotometer
every hour for 14 hours. The acquired signal was adjusted
to the cell number and presented as the initial velocity of
the substrate cleavage reaction (V0), relative to control.
V0 was determined as a slope of the curve – the fluorescent
signal plotted versus time – using linear regression
(GraphPad Software, Inc).
Cell invasion
Transwell inserts (6.5 mm, 8 μm pores, Costar) were
coated with Matrigel™ (Becton Dickinson). Complete cell
culture media was used as attractant for migrating cells.
5’000 cells/insert for HT1080 cells and 8’000 cells/insert
for U251 cell were seeded in 200 μL of serum-free
media. Patupilone was added to cells at the moment of
seeding and cells were irradiated 4 h thereafter. Cells
were allowed to migrate for 24 h. For quantification,
cells from the upper side of the insert were scraped
away, inserts were fixed in Methanol/Acetic acid (75%/
25%, v/v) and stained with DAPI. Invaded cells were
counted manually under a fluorescent microscope or
using the software (Imaris, Bitplane). Each experiment
was carried out in quadruplicates.
Quantitative real time PCR (qRT-PCR)
The total mRNA was isolated with RNeasy Plus Mini Kit
(Qiagen). Reverse transcriptase reaction was conducted
with 1 μg of mRNA with High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems). qRT-PCR was
performed with Fast SYBR Green Master Mix on 7900H
PCR Instrument (Applied Biosystems). Data were analysed
using RQ-manager software (Applied Biosystems) by
employing ΔΔCt method. The following primers were
used:
MMP-1 F: TGTGGACCATGCCATTGAGAA, R:
TCTGCTTGACCCTCAGAGACC;
MMP-2 F: CTTCCGTCTGTCCCAGGAT, R:
CCCCAT AGAGCTCCTGAATG;
MMP-3 F: GGGCCATCAGAGGAAATG, R:
CACGGTTGGAGGGAAACCTA;
MMP-9 F: GGCCACTACTGTGCCTTTGAG, R:
GATGGCGTCGAAGATGTTCAC;
MMP-14 F: TGGAGGAGACACCCACTTTGA, R:
GCCACCAGGAAGATGTCATTTC;
TIMP-1 F: AGTGGCACTCATTGCTTGTG, R:
TTTTCAGAGCCTTGGAGGAG;
TIMP-2 F: TTTTGCAATGCAGATGTAGTGAT, R:
TCCTTCTCACTGACCGCTTT;
18srRNA F: ATGGCCGTTCTTAGTTGGTG, R:
CGCTGAGCCAGTCAGTGTAG;
TBP F: CGGCTGTTTAACTTCGCTTC, R: TTCTTG
GCAAACCAGAAACC.
Western blot
Western blot was performed as described previously [35].
The following antibodies were used: anti-TIMP-1 and −2
(neutralizing antibodies, R&D systems), anti-β-actin
(Sigma). Western blot films were scanned with transillu-
mination mode and the bands was quantified by Quantity
One 4.6 software (Bio-Rad Laboratories).
Statistical analysis
Statistical analysis was performed using GraphPad Prism
3–5 software (GraphPad Software, Inc.). A comparison
between the groups was performed using t-test. Results
are plotted as mean ± SE; the level of significance was
set at P < 0.05.
Results
Patupilone inhibits IR-induced matrix metalloproteinase
activity
To investigate the impact of IR and patupilone on
secreted MMP activity, we determined the MMP activity
in conditioned cell culture media (CM) derived from the
human fibrosarcoma tumor cell line HT1080 24 h
after treatment with IR and patupilone. A significant,
dose-dependent increase of secreted MMP activity
was observed after irradiation with 2 and 10 Gy of IR
(1.15-fold; p < 0.01 and 2 fold; p < 0.001, respectively).
Treatment with 0.2 nM patupilone alone only minimally
decreased the MMP activity level (0.95 fold, p > 0.05) in
comparison to the basal MMP activity level in CM derived
Furmanova-Hollenstein et al. Radiation Oncology 2013, 8:105 Page 3 of 12
http://www.ro-journal.com/content/8/1/105
from untreated control cells. Interestingly, pretreatment of
cells with 0.2 nM patupilone completely abolished the
IR-induced increase of MMP activity after 2 Gy and
counteracted the irradiation-induced increase of MMP
activity by 40% after 10 Gy of IR (p < 0.0001) (Figure 1A).
A direct inhibitory effect of patupilone on MMPs could
be excluded by addition of the MSA to CM, which did
not affect MMP-activity (data not shown).
Long-term clonogenic survival of the HT1080 cells
was determined after treatment with increasing doses of
IR and patupilone (Figure 1B). Importantly low dose
treatment with IR (2 Gy) or patupilone (0.2 nM), alone
did not reduce clonogenicity of these fibrosarcoma cells.
10 Gy of IR reduced clonogenic cell survival of these
radiation resistant cells to an SF of 0.3, and combined
treatment with patupilone primarily induced an additive
anti-clonogenic effect (Figure 1B). The proliferative activity
of these HT1080 cells was only minimally reduced
after treatment with patupilone (0.2 nM) alone and in
combination with irradiation (10 Gy) (Additional file 1:
Figure S1). Thus, patupilone significantly counteracted
IR-induced MMP activity independent of a putative,
antiproliferative effect of these treatment modalities.
Patupilone does not regulate the expression of matrix
metalloproteinases
To evaluate interference of patupilone and IR with
MMP transcription, quantitative RT-PCR was performed
with mRNA derived from HT1080 cells treated with
0.2 nM patupilone and IR (2 and 10 Gy), alone and
in combination. A small but significant dose dependent-
increase of MMP-2, -9 and −14- transcription (P = 0.002;
P = 0.04-0.008; P = 0.0006, respectively) was induced by IR
as determined 24 h after irradiation. Cellular pretreatment
with patupilone altered neither the basal level of MMP
transcription nor the level of IR-enhanced transcription
(Figure 2A). We also assessed the mRNA levels of MMP-1
and MMP-3 but did not observe any significant changes
under any treatment conditions (data not shown).
To determine interference of patupilone with MMP
transcription by other known inducers of MMP-activity,
cells were treated with phorbol-12-myristate-13-acetate
(PMA), a strong transcriptional inducer of MMPs [36,37].
PMA-treatment upregulated MMP-9- and MMP-1-tran-
scription by 13- and 5-fold, respectively. The proteolytic
activity of MMPs, determined in the CM derived from
PMA-treated cells, doubled after incubation with PMA
(P = 0.0001). Pretreatment with patupilone did not
counteract PMA-induced transcription (Figure 2B) but
again diminished PMA-enhanced MMP-activity, as
determined in CM derived from cells treated with PMA in
combination with patupilone (P = 0.0001, Figure 2C).
Irradiation and patupilone-treatment might affect pro-
tein expression or secretion of matrix metalloproteinases.
We therefore probed intra- and extracellular protein levels
of MMPs (MMP-1, 2, 3, 9, 14) by western blotting
and with gelatine zymography assays in case when no
satisfactory antibody-based detection could be achieved.
Since irradiation of HT1080 cells with 2 Gy only minimally
increased MMP activity (Figure 1A) and mRNA levels
Figure 1 Non-cytotoxic concentration of patupilone
counteracts IR-enhanced MMP activity. A, MMP activity was
determined in the CM derived from HT1080 cells treated with 0.2
nM patupilone and indicated doses of IR. Cells were pretreated with
or without patupilone for 24 h and sham-treated or irradiated with
the indicated doses of IR. The cell culture media was discarded 1 h
after irradiation and cells were incubated for additional 24 h in
serum-free medium to obtain CM, n = 13. B, clonogenic cell survival
of HT1080 cells was determined after treatment with increasing
doses of patupilone and IR, n = 3. *P < 0.05, **P < 0.01, ***P < 0.001.
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(Figure 2A), experiments were performed with 10 Gy of
irradiation. In cellular lysates derived from irradiated
HT1080 cells only a minimal increase of MMP-9 protein
level could be detected. On the other hand, in conditioned
media, the protein level of all MMPs tested (MMP-2, 3)
were slightly increased in response to irradiation (Additional
file 2: Figure S2). These results correspond to the slight IR-
induced increase of MMP-transcription (see above). How-
ever cellular pretreatement with patupilone altered neither
the basal nor the IR-induced protein level of MMP-2, -3
and −9 in conditioned media (Additional file 2: Figure S2).
Thus, the inhibitory, counteracting effect of patupilone on
IR-induced MMP activity is not due to downregulation of
MMP protein expression or secretion.
Treatment with patupilone prevents the extracellular
accumulation of the secreted TIMP-1 and TIMP-2 proteins
MMP activity is regulated on multiple levels, including
proteolytic activation, secretion and interaction with
inhibitory factors [38]. In particular, MMP-activity is
tightly controlled by the endogenous inhibitors TIMP-1
and TIMP-2 [25]. We therefore determined expression
of the TIMPs after single and combined treatment with
patupilone and IR. In response to increasing doses of IR
only a minimal increase of TIMP-1 and TIMP-2
mRNA levels was observed. Patupilone pretreatment
slightly reduced IR (10 Gy)-induced TIMP-1 mRNA-levels.
Basal and IR-induced TIMP-2 mRNA levels were not
affected by pretreatment with patupilone. Similar to
MMP-expression, treatment of cells with PMA specifically
induced transcription of TIMP-1 (up to 2-fold, P = 0.045)
but not of TIMP-2, and again, patupilone did not interfere
with PMA-upregulated transcription of this target gene
(Figure 3A).
Next, we assessed protein levels of TIMP-1 and
TIMP-2 in cell lysates and CM derived from the
HT1080 fibrosarcoma cells, which were treated with IR
and patupilone. In response to irradiation both TIMP-1
and TIMP-2 protein levels were increased in cell lysates
and to a higher extent in CM derived from irradiated
fibrosarcoma cells when compared to cell lysates and
CM derived from control cells (Figure 3B, C). After
treatment with patupilone alone, TIMP-1 and TIMP-2
protein levels were slightly elevated in cell lysates, while
TIMP protein levels in CM did not change. Interestingly
though, pretreatment with patupilone significantly
counteracted the level of IR-enhanced TIMP-2-secretion
(P = 0.02). A similar but not significant trend was also
determined for TIMP-1 after treatment with patupilone
in combination with IR (Figure 3B). Complementary to
the counteracting effect of patupilone to IR-enhanced
TIMP-protein levels in CM, TIMP protein levels in cell
Figure 2 Patupilone does not affect MMP transcription. A, MMP mRNA levels in HT1080 cells were determined using qRT-PCR after treatment
with 0.2 nM patupilone 24 h prior to IR. B and C, HT1080 cells were treated with 0.2 nM patupilone 24 h prior to treatment with PMA (0.65 mM).
mRNA for qRT-PCR (B) and CM for determination of MMP activity (C) were isolated 18 h thereafter, n > 4. The fold increase in mRNA levels and
MMP activity was normalized to the mRNA levels and MMP activity from untreated and sham-irradiated cells.*P < 0.05, **P < 0.01, ***P < 0.001.
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lysates were increased after combined treatment with IR
and patupilone in comparison to cell lysates derived
from cells treated with IR alone (P = 0.04 for TIMP-1;
Figure 3C). These results indicate that patupilone does
not affect basal and IR-induced TIMP-1 and TIMP-2
expression but rather interferes with IR-enhanced secretion
of TIMPs into the CM. Eventually this will result in
reduced TIMP-levels in CM in response to the combined
treatment modality in comparison to treatment with IR
alone.
TIMP-1 and −2 are required to enhance matrix
metalloproteinase activity by IR
To directly assess the role of TIMPs in the IR-dependent
MMP activation process, TIMP-1 and TIMP-2 were
downregulated in HT1080 cells with siRNA directed
against the respective TIMP (Figure 4A). The cellular
response to irradiation in control (siLuc)-transfected cells
was similar to the cellular response in non-transfected cells
(Figure 1A), leading to an IR-dependent increase of MMP
activity in the CM thereof (1.9 ± 0.13 fold, P = 0.0005).
Interestingly, TIMP-1 and TIMP-2-depletion significantly
abolished IR-dependent upregulation of MMP-activity
in the CM (P = 0.02), to the same extent as patupilone-
pretreatment counteracted IR-dependent upregulation
of MMP-activity. Pretreatment of TIMP-depleted cells
with patupilone did not result in an additive, counteractive
effect (Figure 4B).
Additional experiments were perfomed using control
(goat IgG) and TIMP-2-directed neutralizing antibodies
to confirm the putative regulatory effect of TIMP-2 on
the IR-induced MMP-activity. These antibodies were
supplemented to the cell culture media during the whole
course of the treatment with IR and patupilone and to
Figure 3 TIMP-1 and TIMP-2 protein levels are regulated by IR and patupilone. HT1080 cells were treated with patupilone (0.2 nM) and IR
(2, 10 Gy) or PMA (0.65 mM). A, TIMP mRNA levels were determined using qRT-PCR, n > 4. B and C, protein levels of TIMPs were determined by
western blotting in the CM (B) or cell lysate (C). Representative blots are shown; quantification was performed with at least 4 independent
experiments. * indicates a TIMP-1 band, which was still detectable after washing and restaining of the membrane with TIMP-2 antibody.
*P < 0.05, **P < 0.01.
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the serum free cell culture media after irradiation.
MMP-activity in CM of control antibody-treated cells
increased 1.6-fold in response to irradiation (P = 0.0002).
TIMP-2-directed neutralizing antibodies significantly
suppressed IR-dependent upregulation of MMP-activity
(P = 0.007), to an extent as observed by siRNA-mediated
TIMP-2 depletion or by patupilone-pretreatment prior
to irradiation alone (see above). Pretreatment of TIMP-
depleted cells with patupilone did not result in an additive,
counteractive effect with TIMP-directed neutralizing
antibodies (Figure 4C).
Thus, extracellular exposure to anti-TIMP-2-directed
antibodies had the same neutralizing effect on IR-induced
upregulation of MMP activity as siRNA-based depletion
of TIMP-1 or TIMP-2, suggesting that TIMP-2 interferes
with the MMP-activation process at the extracellular site.
Unfortunately no experiments could be performed with
neutralizing anti-TIMP-1 antibodies, due to the lack
of satisfactory neutralizing activity (based on in vitro
evaluation with recombinant TIMP-1 and MMPs; data
not shown). Overall, these data indicate that patupilone
counteracts IR-upregulated MMP-activity through inter-
ference with the TIMP-1 and TIMP-2 protein levels
and that it is rather the activating than the inhibitory
function of TIMP-1 and TIMP-2 that is involved in the
IR-dependent enhancement of MMP-activity.
4-amino-phenylmercuric acetate (APMA) is an or-
ganomercuric activator of MMP zymogens, which will fully
activate pro-MMPs present in the CM and independent
of natural TIMP/MMP activation processes [39]. CMs
derived from patupilone and IR-treated HT1080 cells
were incubated with APMA (1mM) and MMP activity
was determined thereafter. APMA treatment increased
the level of MMP activity in all cell culture conditioned
media samples (control, patupilone and/or irradiation
treated) by 2.1+/−0.16-fold when compared to MMP
activity in the corresponding APMA-untreated CMs
(P < 0.004). No difference in MMP activity levels was
observed between APMA-treated CMs derived from
control and patupilone-treated cells. MMP activity in
Figure 4 TIMP protein levels determine IR-enhanced MMP activity. A, effectiveness of protein downregulation by siRNA was assessed in the
CM (96 h after transfection) and in cell lysate (L) by western blotting; representative blots are shown. A densitometric analysis of the TIMP-levels
in the cell lysates, normalized to the loading control, was performed. B, MMP-activity in CM derived from siLuc-, siTIMP-1- and siTIMP-2
-transfected HT1080 cells treated with 0.2 nM patupilone and 10 Gy IR, n ≥ 4. Cell treatment started 72 h after siRNA-transfection. C, HT1080 cells
were incubated with anti-TIMP-2 or isotype control antibodies in parallel with patupilone (0.2 nM) and IR (10 Gy), n ≥ 4. D, CM, derived from
HT1080 cells treated with patupilone (0.2 nM) and IR (10 Gy), was incubated with APMA for 1 h, n = 5. The fold increase in MMP activity was
normalized to the activity in patupilone-untreated and sham-irradiated cells (B, C) and APMA-treated cells (D).*P < 0.05, **P < 0.01, ***P < 0.001.
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the APMA-incubated CM derived from irradiated cells
was further enhanced, when compared to the MMP
activity in the APMA-activated control CM (P = 0.02).
Interestingly, the MMP activity levels in the APMA-
incubated CM derived from irradiated cells and cells
treated with the combined treatment modality did not
significantly differ. Thus, the counteracting effect of
patupilone on IR-induced MMP activity could not anymore
be observed after incubation of the respective CMs
with APMA (Figure 4D). These results corroborate
that patupilone counteracts IR-induced MMP activation
presumably on the level of pro-MMP activation processes,
since the inhibitory effect of patupilone could no longer
be observed when pro-MMPs in the CM were forced into
an active state by APMA.
Patupilone inhibits IR-induced cell invasion
Treatment-enhanced matrix metalloproteinase activity
might directly translate into an increased invasive capacity
of the target cells. Therefore, the invasive capacity of
HT1080 cells was determined after treatment with
patupilone and IR, alone and in combination, using a
Transwell invasion assay. Treatment of cells with
patupilone alone slightly decreased the basal invasion rate
of HT1080 cells (to 83%, P = 0.03). Irradiation with 2
Gy resulted in an increased invasive capacity of
HT1080 by 50%, (P < 0.0001) and most importantly,
pretreatment of cells with patupilone completely abrogated
IR-increased cell invasion (P = 0.0004; Figure 5A). The
increase of cell invasion in response to IR could be
attributed to enhanced MMP activity as the specific
MMP inhibitor N-isobutyl-N-[4-methoxyphenylsulfonyl]
glycyl hydroxamic acid (NNGH) inhibited cell invasion of
irradiated cells (Additional file 3: Figure S3).
Depletion of TIMP-1 and TIMP-2 specifically counter-
acted IR-dependent upregulation of MMP-activity in the
CM (Figure 4C, see above). Importantly depletion of
TIMP-1 or TIMP-2 proteins with corresponding siRNAs
also specifically abrogated IR-induced cell invasion
(Figure 5B, P = 0.007 and 0.02 for siTIMP-1 and −2,
respectively). Thus, these results suggest that IR-
induced MMP activity translates into IR-enhanced cell
invasion. Abrogation of IR-enhanced invasive capacity by
patupilone is most probably due to interference with
TIMP protein levels and subsequent pro-MMP activation
processes.
To exclude a cell-line specific effect, matrix metallo-
proteinase activity and the invasive capacity were also
determined in U251 human glioma cells after treatment
with patupilone and IR alone and in combination.
These experiments were performed at a concentration
of patupilone (0.05 nM), that did not reduce clonogenicity
of these cells and only minimally sensitized U251 cells
to IR, and thus, corresponding to an equipotent
concentration of patupilone as used for HT1080 cells
(Figures 1B and 6A). Treatment with patupilone alone
did not alter the basal level of MMP-activity in the CM
derived from U251 cells. Irradiation with 2 and 4 Gy
increased the MMP activity in the CM of U251 cells by
1.5- and 1.7-fold, respectively (P < 0.002), and pretreatment
Figure 5 IR-induced cell invasiveness is inhibited by patupilone
and is dependent on TIMP protein level. Invasiveness of the
HT1080 cells was assessed in the Transwell invasion assay after
treatment with patupilone (0.2 nM) and 2 Gy IR, n > 3 (A) as
indicated in detail in the method section. B, HT1080 cells were
transfected with siLuc, siTIMP-1 and siTIMP-2 prior to treatment with
patupilone and IR, n = 5, followed by the invasion assay. *P < 0.05,
**P < 0.01, ***P < 0.001.
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with patupilone completely abolished this increase
(P < 0.004, Figure 6B). Treatment with 2 Gy of IR resulted
in an increased invasive capacity of U251 cells by 30%
(P = 0.0052), which was again reversed to basal level
when cells were pretreated with patupilone (Figure 6C).
Thus, the results obtained with the U251 human glioma
cells correspond to the IR- and patupilone-dependent
treatment responses as investigated in the HT1080
fibrosarcoma cell model.
Discussion
Here we investigated the regulation of tumor cell-secreted
matrix metalloproteinases in response to treatment with
the promising combined treatment modality of IR with
the clinically relevant MSA patupilone. To our best
knowledge we demonstrated for the first time that a
microtubule stabilizing agent counteracts IR-enhanced
MMP activity and abrogates IR-induced tumor cell inva-
sion. To uncover the molecular mechanism responsible
for this counteracting effect, we determined MMP activity
under different conditions. Patupilone did not alter IR-
induced transcription of MMPs and TIMPs and did not
influence intracellular and extracellular protein levels of
MMPs. Interestingly though, patupilone counteracted
the IR-enhanced cell invasive capacity via reduction of
extracellular TIMP-1 and TIMP-2 protein levels, which
are required for MMP-activation. The direct involvement
of TIMPs in this patupilone-mediated counteracting effect
was mechanistically demonstrated by the use of TIMP-
neutralizing antibodies and in TIMP-depleted cells.
MMP inhibition represents an interesting strategy for
combined treatment with IR, as successfully demonstrated
by Kalinski et al. [40]. Previous investigations revealed that
patupilone is a potent inhibitor of tumor cell proliferation
under hypoxic and normoxic conditions, has anti-angio-
genic properties, and radiosensitizes in vivo and in vitro
[14,15,17,18,41-43]. In addition, as demonstrated in this
study, patupilone inhibits IR-induced activity of secreted
MMPs and IR-induced cell invasiveness. This aspect
further increases the potency of patupilone as part of a
combined treatment modality with IR and, probably,
with other MMP-activating treatment modalities. At the
same time these in vitro experiments corroborate our
previous investigation on the level of VEGF-secretion that
Figure 6 Patupilone inhibits IR-induced MMP activity and cell
invasion in human U251 glioma cells. A, clonogenic cell survival
of U251 cells was determined after treatment with patupilone and
IR, similar to the experiments performed with the HT1080 cells,
n = 3. B, MMP activity was measured in the CM derived from U251
cells treated with 0.05 nM patupilone and indicated doses of IR,
n = 6. C, cell invasion was assessed using a Transwell invasion assay,
after treatment with 0.05 nM of patupilone and 2 Gy of IR, n > 3.
**P < 0.01, ***P < 0.001. MMP activity and cell invasion assays were
performed similar to the experiments with the HT1080 cells.
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patupilone mechanistically interferes with IR-induced
processes on the tumor cell level [14,19], which eventually
strongly contribute to the supra-additive treatment
response on the in vivo level.
Gene promoter regions of several MMPs contain
putative binding sequences for stress response- and
growth factor-induced transcriptional factors such as AP1
and Nf-κB ([38] and refs therein) and multiple reports
confirmed that different stimuli activate MMPs and
enhance TIMP protein levels via these pathways. IR
was demonstrated to induce MMP-2 and MMP-9 and
subsequently cell invasion via activation of the PI3K/Akt/
Nf-κB pathways both in vitro and in vivo [30,31,40,44-47].
MSAs may disturb MMP activity and the regulatory
function of TIMPs at the level of protein secretion, since
intracellular transport of MMPs and TIMPs depends at
least in part on an intact MT system [20,22]. For example,
treatment with the MSA paclitaxel impaired secretion
of MMP-2 and MMP-9 and significantly reduced the
invasion of melanoma cells [21]. TIMPs can not only
inhibit but also activate MMPs depending on the ratio
of TIMPs and MMPs [48-50]. While TIMP-2 is relevant
for processing of pro-MMP-2, the role of TIMP-1 in
pro-MMP-9 activation has only been predicted based on
the structural similarities of their complexes [51]. In our
study, we corroborated that the TIMP/MMP ratio is of
great importance for pro-MMP activation and may be
deregulated in response to different treatment modalities,
and further demonstrated that both TIMP-2 and TIMP-1
are important for MMP activation after radiation
treatment. IR failed to enhance MMP activity to a large
extent when the protein level of secreted TIMP-1 or
TIMP-2 were downregulated by siRNA, neutralizing
antibodies or patupilone treatment. Unfortunately and
in part due to technical limitations, we could not identify
which specific MMP is thereby affected and eventually
responsible for the deregulated invasive capacity. Future
studies will focus on a putative MMP redundancy and the
specific molecular mechanisms of how MSAs and the
microtubular dynamics interfere with the intracellular
TIMP secretory processes.
MMPs play an important role in cancer progression,
remodelling the extracellular matrix and processing
multiple biologically active factors. MMPs are upregulated
in multiple tumor types and their overexpression correlate
with the aggressiveness of the disease. IR-enhanced cell
invasion was mainly observed after irradiation with low
doses of IR up to 2 Gy. This is most probably due to the
concomitant IR-induced cytotoxicity at higher doses,
which renders it difficult to differentiate between the two
opposing processes. However, cell invasion induced by
low radiation doses is of particular importance in the
context of fractionated radiation schedules and sub-lethal
irradiation of peripheral tumor cells of the radiotherapy
treatment volume. Of particular interest is that the
counteracting effect of patupilone could also be demon-
strated in human glioma cells. Glioblastoma (or grade IV
glioma) is one of the most treatment-resistant primary
tumors in adults and overall survival still remains at a low
rate of 14 months. A major reason for poor prognosis is
extensive infiltration of surrounding brain tissue by tumor
cells and the blood–brain barrier as an obstacle for the
adequate delivery of cytotoxic agents [52]. Radiation
therapy is a standard treatment for gliomas and to our
best knowledge, we have demonstrated, for the first
time, that patupilone can counteract IR-induced activity of
secreted MMPs and a subsequent increase of the invasive
capacity of glioma cells. The ability of patupilone to cross
the blood–brain barrier and to retain in brain tissues [42]
renders patupilone as a single treatment modality a very
potent and promising chemotherapeutical agent for brain
malignancies [11]. But in addition to the direct cytotoxic
and radiosensitizing effect of patupilone, a combined
treatment modality of IR with patupilone might minimize
the risk for IR-induced glioma cell migration and
dissemination, mediated by IR-upregulated MMPs [53,54].
However, beyond controlling tumor cell dissemination
and due to the complex MMP functions in cancer
progression and treatment resistance, the combined
treatment modality of IR and patupilone might be of a
great clinical benefit also for other malignancies.
Conclusions
Previous investigations revealed additive cytotoxicity of IR
with the microtubule stabilizing agent patupilone in vitro
with a strong supra-additive effect in vivo. Here we mech-
anistically demonstrate in vitro that patupilone abrogates
IR-induced metalloproteinase-activity and IR-induced inva-
sive capacity of tumor cells. Since IR-induced MMP activity
may limit tumor control and may even promote tumor
progression, these results suggest an additional rationale to
combine ionizing radiation with the microtubule interfering
agent patupilone. Eventually these in vitro experiments
corroborate our previous investigations that patupilone
mechanistically interferes with IR-induced processes on the
tumor cell level, which might strongly contribute to the
supra-additive treatment response on the in vivo level.
Additional files
Additional file 1: Figure S1. Proliferative activity of HT1080 cells 24 h
after treatment with patupilone, IR and in combination. The proliferative
activity of these HT1080 cells was only minimally and not significantly
reduced after treatment with patupilone alone and in combination with
irradiation. In case of the combined treatment the cells were treated with
patupilone (0.2 nM) 24 h prior to IR (10 Gy). Proliferative activity was
measured with the MTT-like Alamar Blue colorimetric proliferation assay
24 hours after IR. Mean +/− SD are shown of 3 independent experiments
performed in triplicate.
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Additional file 2: Figure S2. mRNA and protein levels of MMPs after
treatment. A, MMP-1 and −3 mRNA levels were determined using qRT-PCR
in HT1080 cells treated with 0.2 nM patupilone 24 h prior to IR (10 Gy). RNA
was isolated 18 h thereafter. B, The MMP protein levels in HT1080 cells were
determined in the CM by western blotting (top) and by gelatine
zymography (middle) and in the whole cell lysates by western blotting
(bottom). The cells were treated with 0.2 nM patupilone 24 h before 10 Gy
IR or application of 40 mg/ml PMA. 24 h thereafter, the cell lysates and CM
were collected. N > 4.
Additional file 3: Figure S3. The MMP inhibitor NNGH inhibits cell
invasion. Cells were plated with NNGH (10 mM) 4 h prior to irradiation.
The rate of invasion was evaluated 24 h after plating. The results are
plotted as percentage of the invading cells relative to control.
Mean +/− SE, n > 3, *P < 0.05, **P < 0.01, ***P < 0.001.
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